Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How AI will transform mental health support for patients with breast cancer

2.

Asymptomatic or Minimally Symptomatic Myelofibrosis

3.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

4.

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

5.

High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot